Re: Addendum to Trademark License and Supply Agreement dated May 28, 2014 Dear Stephen,Addendum to Trademark License and Supply Agreement • November 6th, 2015 • Retrophin, Inc. • Pharmaceutical preparations
As you are aware, Retrophin has requested that Mission Pharmacal build a significant safety stock of tiopronin, the active pharmaceutical ingredient (API) in THIOLA. The safety stock is requested to insure that there is no interruption in the supply of THIOLA and to prepare for a potential development project, whereby THIOLA may be reformulated. Due to the financial burden of purchasing such large quantities of tiopronin prior to firm production orders, Mission is requesting immediate reimbursement for the safety stock purchases.
AMENDMENT NO. 4 TO SUBLICENSE AGREEMENTSublicense Agreement • November 6th, 2015 • Retrophin, Inc. • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 4 TO SUBLICENSE AGREEMENT (the "Amendment") is made and entered into as of September 17, 2015 ("Amendment Effective Date") and amends the Sublicense Agreement effective as of February 16, 2012, as amended pursuant to that certain Amendment to Sublicense Agreement dated December 11, 2012, Amendment No. 2 to Sublicense Agreement dated January 7, 2013, and Amendment No. 3 to Sublicense Agreement dated February 27, 2015 (the "Sublicense Agreement") by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 and its wholly owned subsidiary, Pharmacopeia, LLC (as successor in interest to Pharmacopeia Drug Discovery Inc.) ("PCOP"), a limited liability company organized under the laws of Delaware and having a place of business at 11119 North Torrey Pines Road, Suite 200, La Jolla, CA, 92037 (collectively, Ligand Pharmaceuticals Incorporat
